Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | GHSR | Q92847 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4787915 | 1.00 | MLNR (1.00) | MLNRCYP3A4CYP2D6GHSRCYP1A2 | |
| SCHEMBL5127355 | 0.91 | MLNR (0.83) | MLNRCYP3A4CYP2D6GHSRCYP1A2 | |
| SCHEMBL5120503 | 0.90 | MLNR (0.82) | MLNRCYP3A4CYP2D6GHSRCYP1A2 | |
| SCHEMBL5127685 | 0.86 | MLNR (0.75) | MLNRCYP3A4CYP2D6GHSRCYP1A2 | |
| SCHEMBL4789508 | 0.81 | MLNR (1.00) | MLNRCYP3A4CYP2D6GHSRCYP1A2 | |
| SCHEMBL5120467 | 0.81 | MLNR (0.69) | MLNRCYP3A4CYP2D6GHSRCYP1A2 | |
| SCHEMBL5131588 | 0.81 | MLNR (1.00) | MLNRCYP3A4CYP2D6GHSRCYP1A2 | |
| SCHEMBL4752136 | 0.80 | MLNR (0.67) | MLNRCYP3A4CYP2D6GHSRCYP1A2 | |
| SCHEMBL1704769 | 0.80 | MLNR (1.00) | MLNRCYP3A4CYP2D6GHSRCYP1A2 | |
| SCHEMBL377500 | 0.78 | MLNR (0.73) | MLNRCYP3A4CYP2D6GHSRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312209-A1 | Piperazine Heteroaryl Derivatives as Gpr38 Agonists | GLAXO GROUP LIMITED | 2008-12-18 | — | — | US | claimed |
| US-20080312209-A1 | Piperazine Heteroaryl Derivatives as Gpr38 Agonists | GLAXO GROUP LIMITED | 2008-12-18 | — | — | US | disclosed |
| US-20080312209-A1 | Piperazine Heteroaryl Derivatives as Gpr38 Agonists | GLAXO GROUP LIMITED | 2008-12-18 | — | — | US | disclosed |
| US-20080312209-A1 | Piperazine Heteroaryl Derivatives as Gpr38 Agonists | GLAXO GROUP LIMITED | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312209-A1 | Piperazine Heteroaryl Derivatives as Gpr38 Agonists | GPR68, GPR55, GPR88 | MLNR 207/4885CYP3A4 784/4885CYP2D6 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.